Table of Content

1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation


2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions


3. EXECUTIVE SUMMARY
3.1. Research Highlights


4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis


5. GLOBAL CANCER VACCINES MARKET ANALYSIS, BY TECHNOLGY
5.1. Introduction
5.2. Dendritic Cells (DC) Cancer Vaccines
5.3. Recombinant Cancer Vaccines
5.4. Antigen/Adjuvant Cancer Vaccines
5.5. Whole-Cell Cancer Vaccines
5.6. Viral Vector & DNA Cancer Vaccines
5.7. Others


6. GLOBAL CANCER VACCINES MARKET ANALYSIS, BY TYPE
6.1. Introduction
6.2. Preventive Cancer Vaccines
6.3. Therapeutic Cancer Vaccines


7. GLOBAL CANCER VACCINES MARKET ANALYSIS, BY APPLICATION
7.1. Introduction
7.2. Cervical Cancer
7.3. Prostate Cancer
7.4. Others


8. GLOBAL CANCER VACCINES MARKET ANALYSIS, BY END-USE
8.1. Introduction
8.2. Pediatrics
8.3. Adults


9. GLOBAL CANCER VACCINES MARKET ANALYSIS, BY GEOGRAPHY?
9.1. Introduction
9.2. North America
9.2.1. USA
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Others
9.5. Middle East and Africa
9.5.1. UAE
9.5.2. South Africa
9.5.3. Israel
9.5.4. Saudi Arabia
9.5.5. Others
9.6. Asia Pacific
9.6.1. China
9.6.2. Japan
9.6.3. India
9.6.4. Australia
9.6.5. Taiwan
9.6.6. South Korea
9.6.7. Others


10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix


11. COMPANY PROFILES
11.1. AstraZeneca plc
11.2. GlaxoSmithKline plc.
11.3. Merck & Co., Inc.
11.4. Pfizer Inc.
11.5. Moderna Inc.
11.6. OSE Therapeutics
11.7. Nouscom
11.8. OncBioMune Pharmaceuticals Inc.
11.9. Sanofi S.A.
11.10. Bristol-Myers Squibb